Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$2.28
At close: Jun 11 EDT
$2.35
0.073.02%
Pre-Market: 6:53 PM EDT
Comments
Loading...
Maravai LifeSciences Analyst Ratings and Price Targets | NASDAQ:MRVI | Benzinga
Maravai LifeSciences Holdings Inc has a consensus price target of $10.65 based on the ratings of 15 analysts. The high is $35 issued by Goldman Sachs on July 14, 2022. The low is $2 issued by Baird on May 13, 2025. The 3 most-recent analyst ratings were released by Craig-Hallum, Baird, and Morgan Stanley on May 13, 2025, May 13, 2025, and March 25, 2025, respectively. With an average price target of $5.67 between Craig-Hallum, Baird, and Morgan Stanley, there's an implied 141.25% upside for Maravai LifeSciences Holdings Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Craig-Hallum
Baird
Morgan Stanley
UBS
B of A Securities
1calculated from analyst ratings
Analyst Ratings for Maravai LifeSciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/13/2025 | Buy Now | 325.73% | Craig-Hallum | Christian Schwab74% | $12 → $10 | Maintains | Buy | Get Alert |
| 05/13/2025 | Buy Now | -14.85% | Baird | Catherine Schulte66% | $3 → $2 | Maintains | Neutral | Get Alert |
| 03/25/2025 | Buy Now | 112.87% | Morgan Stanley | Tejas Savant50% | $7 → $5 | Maintains | Equal-Weight | Get Alert |
| 03/21/2025 | Buy Now | 6.43% | UBS | Dan Brennan63% | $8 → $2.5 | Maintains | Neutral | Get Alert |
| 03/03/2025 | Buy Now | 240.58% | B of A Securities | Michael Ryskin46% | $9 → $8 | Maintains | Buy | Get Alert |
| 02/26/2025 | Buy Now | 27.72% | Baird | Catherine Schulte66% | $9 → $3 | Downgrade | Outperform → Neutral | Get Alert |
| 12/05/2024 | Buy Now | 80.94% | Goldman Sachs | Matthew Sykes64% | $7 → $4.25 | Downgrade | Neutral → Sell | Get Alert |
| 11/14/2024 | Buy Now | — | Wolfe Research | Doug Schenkel72% | — | Initiates | → Peer Perform | Get Alert |
| 11/08/2024 | Buy Now | 453.45% | RBC Capital | Conor McNamara36% | $17 → $13 | Maintains | Outperform | Get Alert |
| 11/08/2024 | Buy Now | — | William Blair | Matt Larew25% | — | Downgrade | Outperform → Market Perform | Get Alert |
| 11/08/2024 | Buy Now | 283.16% | Baird | Catherine Schulte66% | $10 → $9 | Maintains | Outperform | Get Alert |
| 10/08/2024 | Buy Now | 198.01% | Goldman Sachs | Matthew Sykes64% | $8 → $7 | Maintains | Neutral | Get Alert |
| 08/27/2024 | Buy Now | 325.73% | Wells Fargo | Brandon Couillard68% | → $10 | Initiates | → Overweight | Get Alert |
| 08/16/2024 | Buy Now | 538.6% | RBC Capital | Conor McNamara36% | $15 → $15 | Reiterates | Outperform → Outperform | Get Alert |
| 08/13/2024 | Buy Now | 325.73% | Morgan Stanley | Tejas Savant50% | $11 → $10 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 08/08/2024 | Buy Now | 240.58% | Goldman Sachs | Matthew Sykes64% | $7 → $8 | Maintains | Neutral | Get Alert |
| 08/08/2024 | Buy Now | 368.3% | UBS | Dan Brennan63% | $8.5 → $11 | Maintains | Neutral | Get Alert |
| 07/09/2024 | Buy Now | 198.01% | Goldman Sachs | Matthew Sykes64% | $8 → $7 | Maintains | Neutral | Get Alert |
| 05/09/2024 | Buy Now | 325.73% | Baird | Catherine Schulte66% | $8 → $10 | Maintains | Outperform | Get Alert |
| 04/10/2024 | Buy Now | 538.6% | Craig-Hallum | Christian Schwab74% | → $15 | Initiates | → Buy | Get Alert |
| 02/23/2024 | Buy Now | 496.02% | RBC Capital | Conor McNamara36% | $12 → $14 | Maintains | Outperform | Get Alert |
| 02/23/2024 | Buy Now | 325.73% | Stifel | Daniel Arias78% | $11 → $10 | Maintains | Buy | Get Alert |
| 12/12/2023 | Buy Now | 240.58% | B of A Securities | Michael Ryskin46% | $10 → $8 | Upgrade | Neutral → Buy | Get Alert |
| 11/09/2023 | Buy Now | 198.01% | Goldman Sachs | Matthew Sykes64% | $8 → $7 | Maintains | Neutral | Get Alert |
| 11/09/2023 | Buy Now | 368.3% | Morgan Stanley | Tejas Savant50% | $12 → $11 | Maintains | Overweight | Get Alert |
| 08/09/2023 | Buy Now | 410.88% | Morgan Stanley | Tejas Savant50% | $27 → $12 | Maintains | Overweight | Get Alert |
| 08/08/2023 | Buy Now | 623.74% | Deutsche Bank | Justin Bowers46% | $23 → $17 | Maintains | Buy | Get Alert |
| 08/08/2023 | Buy Now | 666.32% | RBC Capital | Conor McNamara36% | $20 → $18 | Maintains | Outperform | Get Alert |
| 08/08/2023 | Buy Now | 240.58% | Goldman Sachs | Matthew Sykes64% | $12 → $8 | Maintains | Neutral | Get Alert |
| 08/08/2023 | Buy Now | 368.3% | Baird | Catherine Schulte66% | $18 → $11 | Maintains | Outperform | Get Alert |
| 08/08/2023 | Buy Now | 368.3% | Credit Suisse | Dan Leonard55% | $14 → $11 | Maintains | Neutral | Get Alert |
| 08/08/2023 | Buy Now | — | Keybanc | Paul Knight54% | — | Downgrade | Overweight → Sector Weight | Get Alert |
| 05/23/2023 | Buy Now | 496.02% | Credit Suisse | Dan Leonard55% | $18 → $14 | Downgrade | Outperform → Neutral | Get Alert |
| 05/10/2023 | Buy Now | 453.45% | Goldman Sachs | Matthew Sykes64% | $16 → $13 | Maintains | Neutral | Get Alert |
| 05/10/2023 | Buy Now | 1049.47% | Morgan Stanley | Tejas Savant50% | $29 → $27 | Maintains | Overweight | Get Alert |
| 05/09/2023 | Buy Now | 751.46% | RBC Capital | Conor McNamara36% | $22 → $20 | Maintains | Outperform | Get Alert |
| 05/09/2023 | Buy Now | 453.45% | Goldman Sachs | Matthew Sykes64% | $16 → $13 | Downgrade | Buy → Neutral | Get Alert |
| 05/09/2023 | Buy Now | 879.18% | Deutsche Bank | Justin Bowers46% | $25 → $23 | Maintains | Buy | Get Alert |
| 05/09/2023 | Buy Now | 666.32% | Credit Suisse | Dan Leonard55% | $23 → $18 | Maintains | Outperform | Get Alert |
| 02/24/2023 | Buy Now | 1134.62% | Morgan Stanley | Tejas Savant50% | $32 → $29 | Maintains | Overweight | Get Alert |
| 02/23/2023 | Buy Now | 836.61% | Baird | Catherine Schulte66% | $25 → $22 | Maintains | Outperform | Get Alert |
| 02/23/2023 | Buy Now | 879.18% | Credit Suisse | Dan Leonard55% | $26 → $23 | Maintains | Outperform | Get Alert |
| 02/23/2023 | Buy Now | 921.75% | Keybanc | Paul Knight54% | $28 → $24 | Maintains | Overweight | Get Alert |
| 01/17/2023 | Buy Now | 581.17% | Goldman Sachs | Matthew Sykes64% | $18 → $16 | Maintains | Buy | Get Alert |
| 01/05/2023 | Buy Now | 581.17% | UBS | Dan Brennan63% | $20 → $16 | Downgrade | Buy → Neutral | Get Alert |
| 12/14/2022 | Buy Now | 964.33% | Deutsche Bank | Justin Bowers46% | → $25 | Initiates | → Buy | Get Alert |
| 12/07/2022 | Buy Now | 836.61% | RBC Capital | Conor McNamara36% | → $22 | Initiates | → Outperform | Get Alert |
| 11/04/2022 | Buy Now | 666.32% | Goldman Sachs | Matthew Sykes64% | $30 → $18 | Maintains | Buy | Get Alert |
| 11/04/2022 | Buy Now | 1262.34% | Morgan Stanley | Tejas Savant50% | $35 → $32 | Maintains | Overweight | Get Alert |
| 11/03/2022 | Buy Now | 623.74% | B of A Securities | Michael Ryskin46% | $32 → $17 | Downgrade | Buy → Neutral | Get Alert |
| 11/03/2022 | Buy Now | 1006.9% | Credit Suisse | Dan Leonard55% | $34 → $26 | Maintains | Outperform | Get Alert |
| 11/03/2022 | Buy Now | 1092.05% | Keybanc | Paul Knight54% | $35 → $28 | Maintains | Overweight | Get Alert |
| 08/25/2022 | Buy Now | 1347.49% | Credit Suisse | Dan Leonard55% | → $34 | Initiates | → Outperform | Get Alert |
| 08/08/2022 | Buy Now | 1390.06% | Morgan Stanley | Tejas Savant50% | $49 → $35 | Maintains | Overweight | Get Alert |
| 07/14/2022 | Buy Now | 1390.06% | Goldman Sachs | — | $44 → $35 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Maravai LifeSciences (MRVI) stock?
The latest price target for Maravai LifeSciences (NASDAQ:MRVI) was reported by Craig-Hallum on May 13, 2025. The analyst firm set a price target for $10.00 expecting MRVI to rise to within 12 months (a possible 325.73% upside). 18 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Maravai LifeSciences (MRVI)?
The latest analyst rating for Maravai LifeSciences (NASDAQ:MRVI) was provided by Craig-Hallum, and Maravai LifeSciences maintained their buy rating.
When was the last upgrade for Maravai LifeSciences (MRVI)?
The last upgrade for Maravai LifeSciences Holdings Inc happened on December 12, 2023 when B of A Securities raised their price target to $8. B of A Securities previously had a neutral for Maravai LifeSciences Holdings Inc.
When was the last downgrade for Maravai LifeSciences (MRVI)?
The last downgrade for Maravai LifeSciences Holdings Inc happened on February 26, 2025 when Baird changed their price target from $9 to $3 for Maravai LifeSciences Holdings Inc.
When is the next analyst rating going to be posted or updated for Maravai LifeSciences (MRVI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Maravai LifeSciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Maravai LifeSciences was filed on May 13, 2025 so you should expect the next rating to be made available sometime around May 13, 2026.
Is the Analyst Rating Maravai LifeSciences (MRVI) correct?
While ratings are subjective and will change, the latest Maravai LifeSciences (MRVI) rating was a maintained with a price target of $12.00 to $10.00. The current price Maravai LifeSciences (MRVI) is trading at is $2.35, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
